Latest News
Zentalis Pharmaceuticals, Inc.
- Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
- ESMO: Zentalis already dreaming of launch for WEE1 inhibitor after ‘great result’ in early-stage test
- Zentalis Validates a Multibillion-Dollar Cancer Market as Aprea Therapeutics Emerges as a Next-Generation Contender
- Zentalis stock rises on cancer trial data (ZNTL:NASDAQ)
- What Zentalis Pharmaceuticals’ (NASDAQ: ZNTL) DENALI Survival Data Means for Its Cyclin E1 Strategy
- Zentalis reports survival data from azenosertib ovarian cancer study
- Zentalis reports survival data for azenosertib in ovarian cancer trial
- Zentalis Pharmaceuticals reports 15.8‑month survival in ovarian cancer subgroup
- Zentalis Pharmaceuticals Says Median Overall Survival Of 15.8 Months With Azenosertib In Cyclin E1-Positive Proc
- Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
- Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
- Zentalis reports 15.8-month median survival for ovarian cancer patients on azenosertib in DENALI study
Headlines from the last 30 days, linking to the original publishers. See all market news →